Cargando…

Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients

BACKGROUND: The objective of this study was to determine the prevalence of intestinal parasites, with special emphasis on microsporidia and Cryptosporidium, as well as their association with human immunodeficiency virus (HIV) symptoms, risk factors, and other digestive parasites. We also wish to det...

Descripción completa

Detalles Bibliográficos
Autores principales: Wumba, Roger, Longo-Mbenza, Benjamin, Menotti, Jean, Mandina, Madone, Kintoki, Fabien, Situakibanza, Nani Hippolyte, Kakicha, Marie Kapepela, Zanga, Josue, Mbanzulu-Makola, Kennedy, Nseka, Tommy, Mukendi, Jean Pierre, Kendjo, Eric, Sala, Jean, Thellier, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422901/
https://www.ncbi.nlm.nih.gov/pubmed/22924007
http://dx.doi.org/10.2147/IJGM.S32344
_version_ 1782241065600811008
author Wumba, Roger
Longo-Mbenza, Benjamin
Menotti, Jean
Mandina, Madone
Kintoki, Fabien
Situakibanza, Nani Hippolyte
Kakicha, Marie Kapepela
Zanga, Josue
Mbanzulu-Makola, Kennedy
Nseka, Tommy
Mukendi, Jean Pierre
Kendjo, Eric
Sala, Jean
Thellier, Marc
author_facet Wumba, Roger
Longo-Mbenza, Benjamin
Menotti, Jean
Mandina, Madone
Kintoki, Fabien
Situakibanza, Nani Hippolyte
Kakicha, Marie Kapepela
Zanga, Josue
Mbanzulu-Makola, Kennedy
Nseka, Tommy
Mukendi, Jean Pierre
Kendjo, Eric
Sala, Jean
Thellier, Marc
author_sort Wumba, Roger
collection PubMed
description BACKGROUND: The objective of this study was to determine the prevalence of intestinal parasites, with special emphasis on microsporidia and Cryptosporidium, as well as their association with human immunodeficiency virus (HIV) symptoms, risk factors, and other digestive parasites. We also wish to determine the molecular biology definitions of the species and genotypes of microsporidia and Cryptosporidium in HIV patients. METHODS: In this cross-sectional study, carried out in Kinshasa, Democratic Republic of the Congo, stool samples were collected from 242 HIV patients (87 men and 155 women) with referred symptoms and risk factors for opportunistic intestinal parasites. The analysis of feces specimen were performed using Ziehl–Neelsen stainings, real-time polymerase chain reaction (PCR), immunofluorescence indirect monoclonal antibody, nested PCR-restriction fragment length polymorphism, and PCR amplification and sequencing. Odds ratio (OR) and 95% confidence intervals were used to quantify the risk. RESULTS: Of the 242 HIV patients, 7.8%, 0.4%, 5.4%, 0.4%, 2%, 10.6%, and 2.8% had Enterocytozoon bieneusi, Encephalitozoon intestinalis, Cryptosporidium spp., Isospora belli, pathogenic intestinal protozoa, nonpathogenic intestinal protozoa, and helminths, respectively. We found five genotypes of E. bieneusi: two older, NIA1 and D, and three new, KIN1, KIN2, and KIN3. Only 0.4% and 1.6% had Cryptosporidium parvum and Cryptosporidium hominis, respectively. Of the patients, 36.4%, 34.3%, 31%, and 39% had asthenia, diarrhea, a CD4 count of <100 cells/mm(3), and no antiretroviral therapy (ART), respectively. The majority of those with opportunistic intestinal parasites and C. hominis, and all with C. parvum and new E. bieneusi genotypes, had diarrhea, low CD4+ counts of <100 cells/mm(3), and no ART. There was a significant association between Entamoeba coli, Kaposi sarcoma, herpes zoster, chronic diarrhea, and asthenia, and the presence of 28 cases with opportunistic intestinal parasites. Rural areas, public toilets, and exposure to farm pigs were the univariate risk factors present in the 28 cases with opportunistic intestinal parasites. In logistic regression analysis, a CD4 count of <100 cells/mm(3) (OR = 4.60; 95% CI 1.70–12.20; P = 0.002), no ART (OR = 5.00; 95% CI 1.90–13.20; P < 0.001), and exposure to surface water (OR = 2.90; 95% CI 1.01–8.40; P = 0.048) were identified as the significant and independent determinants for the presence of opportunistic intestinal parasites. CONCLUSION: E. bieneusi and Cryptosporidium are becoming more prevalent in Kinshasa, Congo. Based on the findings, we recommend epidemiology surveillance and prevention by means of hygiene, the emphasis of sensitive PCR methods, and treating opportunistic intestinal parasites that may be acquired through fecal–oral transmission, surface water, normal immunity, rural area-based person–person and animal–human infection, and transmission of HIV. Therapy, including ART and treatment with fumagillin, is needed.
format Online
Article
Text
id pubmed-3422901
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34229012012-08-24 Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients Wumba, Roger Longo-Mbenza, Benjamin Menotti, Jean Mandina, Madone Kintoki, Fabien Situakibanza, Nani Hippolyte Kakicha, Marie Kapepela Zanga, Josue Mbanzulu-Makola, Kennedy Nseka, Tommy Mukendi, Jean Pierre Kendjo, Eric Sala, Jean Thellier, Marc Int J Gen Med Original Research BACKGROUND: The objective of this study was to determine the prevalence of intestinal parasites, with special emphasis on microsporidia and Cryptosporidium, as well as their association with human immunodeficiency virus (HIV) symptoms, risk factors, and other digestive parasites. We also wish to determine the molecular biology definitions of the species and genotypes of microsporidia and Cryptosporidium in HIV patients. METHODS: In this cross-sectional study, carried out in Kinshasa, Democratic Republic of the Congo, stool samples were collected from 242 HIV patients (87 men and 155 women) with referred symptoms and risk factors for opportunistic intestinal parasites. The analysis of feces specimen were performed using Ziehl–Neelsen stainings, real-time polymerase chain reaction (PCR), immunofluorescence indirect monoclonal antibody, nested PCR-restriction fragment length polymorphism, and PCR amplification and sequencing. Odds ratio (OR) and 95% confidence intervals were used to quantify the risk. RESULTS: Of the 242 HIV patients, 7.8%, 0.4%, 5.4%, 0.4%, 2%, 10.6%, and 2.8% had Enterocytozoon bieneusi, Encephalitozoon intestinalis, Cryptosporidium spp., Isospora belli, pathogenic intestinal protozoa, nonpathogenic intestinal protozoa, and helminths, respectively. We found five genotypes of E. bieneusi: two older, NIA1 and D, and three new, KIN1, KIN2, and KIN3. Only 0.4% and 1.6% had Cryptosporidium parvum and Cryptosporidium hominis, respectively. Of the patients, 36.4%, 34.3%, 31%, and 39% had asthenia, diarrhea, a CD4 count of <100 cells/mm(3), and no antiretroviral therapy (ART), respectively. The majority of those with opportunistic intestinal parasites and C. hominis, and all with C. parvum and new E. bieneusi genotypes, had diarrhea, low CD4+ counts of <100 cells/mm(3), and no ART. There was a significant association between Entamoeba coli, Kaposi sarcoma, herpes zoster, chronic diarrhea, and asthenia, and the presence of 28 cases with opportunistic intestinal parasites. Rural areas, public toilets, and exposure to farm pigs were the univariate risk factors present in the 28 cases with opportunistic intestinal parasites. In logistic regression analysis, a CD4 count of <100 cells/mm(3) (OR = 4.60; 95% CI 1.70–12.20; P = 0.002), no ART (OR = 5.00; 95% CI 1.90–13.20; P < 0.001), and exposure to surface water (OR = 2.90; 95% CI 1.01–8.40; P = 0.048) were identified as the significant and independent determinants for the presence of opportunistic intestinal parasites. CONCLUSION: E. bieneusi and Cryptosporidium are becoming more prevalent in Kinshasa, Congo. Based on the findings, we recommend epidemiology surveillance and prevention by means of hygiene, the emphasis of sensitive PCR methods, and treating opportunistic intestinal parasites that may be acquired through fecal–oral transmission, surface water, normal immunity, rural area-based person–person and animal–human infection, and transmission of HIV. Therapy, including ART and treatment with fumagillin, is needed. Dove Medical Press 2012-07-19 /pmc/articles/PMC3422901/ /pubmed/22924007 http://dx.doi.org/10.2147/IJGM.S32344 Text en © 2012 Wumba et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Wumba, Roger
Longo-Mbenza, Benjamin
Menotti, Jean
Mandina, Madone
Kintoki, Fabien
Situakibanza, Nani Hippolyte
Kakicha, Marie Kapepela
Zanga, Josue
Mbanzulu-Makola, Kennedy
Nseka, Tommy
Mukendi, Jean Pierre
Kendjo, Eric
Sala, Jean
Thellier, Marc
Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients
title Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients
title_full Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients
title_fullStr Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients
title_full_unstemmed Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients
title_short Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients
title_sort epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among hiv/aids patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422901/
https://www.ncbi.nlm.nih.gov/pubmed/22924007
http://dx.doi.org/10.2147/IJGM.S32344
work_keys_str_mv AT wumbaroger epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT longombenzabenjamin epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT menottijean epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT mandinamadone epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT kintokifabien epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT situakibanzananihippolyte epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT kakichamariekapepela epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT zangajosue epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT mbanzulumakolakennedy epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT nsekatommy epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT mukendijeanpierre epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT kendjoeric epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT salajean epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients
AT thelliermarc epidemiologyclinicalimmuneandmolecularprofilesofmicrosporidiosisandcryptosporidiosisamonghivaidspatients